Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DICE Therapeutics
South San Francisco, California, United Statesdicetherapeutics.com ↗
- Ownership
- Private
- Employees
- ~32
- Development stage
- Other
01
Overview
DICE Therapeutics developed oral small molecule inhibitors targeting the IL‑17 pathway for autoimmune and inflammatory diseases. Its lead program, DC‑806, advanced to Phase II trials in moderate-to-severe plaque psoriasis but was discontinued by Eli Lilly after acquisition. The follow-up candidate, DC‑853—designed for improved potency and metabolic stability—has become the new focus and has entered Phase II clinical trials. The company’s proprietary DELSCAPE platform enables discovery of oral drugs against challenging protein-protein interaction targets[6][8].
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Small molecules
- Industry
- Biotech
Beyond the preview
Go deeper on DICE Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DICE Therapeutics.